Spotlight
Clinical
CME
Partners
VitrenASE: Immusol starts trial for potential PVR drug
San Diego-Immusol has begun a phase II clinical trial for its VitrenASE, a potential treatment for proliferative vitreoretinopathy (PVR) that could reduce the incidence of repeat retinal detachment after surgical repair.
Related Videos
Related Content
